Pharmafile Logo
Pharmafocus logo
Advanced Search

iclusig

Showing 5 posts of 5 posts found.

incyte

Incyte acquires Ariad’s European operations in $140 million deal

May 10, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Ariad, Incyte, Operations, buy out, european, iclusig, leukaemia, out-license

Incyte (NASDAQ: INCY) has entered into an agreement with Ariad Pharmaceuticals (NASDAQ: ARIA) that will see the company acquire Ariad’s …

News
Iclusig image

EMA keeps Ariad cancer drug on the market

October 13, 2014
Sales and Marketing Ariad, CML, EMA, PRAC, iclusig, leukaemia, ponatinib

The EMA has recommended Ariad’s leukaemia drug Iclusig (ponatinib) should continue to be used under its current indication despite ongoing …

News
iclusig image

EMA in new Iclusig probe

December 9, 2013
Sales and Marketing Ariad, EMA, iclusig, leukaemia

Europe’s medicines regulator has begun a new review of Ariad Pharmaceuticals’ leukaemia drug Iclusig, looking in particular at the risk …

News
Iclusig image

Ariad cancer drug pulled amid safety fears

November 1, 2013
Sales and Marketing Ariad, FDA, iclusig, leukaemia

Ariad Pharmaceuticals has been forced by the FDA to suspend sales of its blood cancer drug Iclusig given the high …

News
iclusig image

Ariad ditches CML trial

October 21, 2013
Research and Development, Sales and Marketing Ariad, CML, iclusig

Ariad Pharmaceuticals has ditched its late-stage trial of Iclusig in patients with newly-diagnosed chronic myeloid leukemia (CML) after blood clots …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026